AI Article Synopsis
- Arylsulfatase B (ASB) is an enzyme that breaks down specific sulfate compounds in glycosaminoglycans and shows increased activity in mouse models of schistosomiasis.
- The study examined ASB obtained from liver tissues of Schistosoma-infected mice, focusing on how it interacts with the drugs praziquantel and Commiphora extract.
- Praziquantel inhibited ASB activity, while Commiphora extract activated it, but neither drug affected ASB's immune interaction with a polyclonal antibody, suggesting potential therapeutic implications for schistosomiasis treatment.
Article Abstract
Arylsulfatase B (ASB) hydrolyzes the desulfation of N-acetylgalactosamine-4-sulfate at the non-reducing terminal of glycosaminoglycans. This enzyme activity was found to be elevated in mice schistosomiasis. In the present study, the catalytic and immunological properties of purified ASB from the liver of Schistosoma-infected mouse was investigated in the presence and absence of the schistosomicidal drugs praziquantel and Commiphora extract. The in vitro effect of praziquantel was found to be inhibitory with a Ki value of 5.5 x 10(-4) M while that of commiphora extract was as an activator. Furthermore, these drugs did not have an observed effect on the immunological properties of ASB with regard to its binding to its polyclonal rabbit antibody. These results indicate that some schistosomicidal drugs may reverse the alteration of the catalytic properties of the enzyme in schistosomiasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14756360500424036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!